Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Feb. 28, 2022
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus FY  
Trading Symbol GMTX  
Entity Registrant Name Gemini Therapeutics, Inc. /DE  
Entity Central Index Key 0001816736  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
ICFR Auditor Attestation Flag false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   43,208,159
Entity Public Float $ 173,315,118  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Security Exchange Name NASDAQ  
Entity File Number 001-39438  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1612845  
Entity Address, Address Line One Address Not Applicable1  
Entity Ex Transition Period false  
Entity Address, Postal Zip Code Address Not Applicable1  
City Area Code 617  
Local Phone Number 401-4400  
Document Annual Report true  
Document Transition Report false  
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

None.

 

 

1 In January 2022, the Company became a remote-first company. Accordingly, the Company does not currently maintain a physical headquarters.

  
Auditor Firm ID 42  
Auditor Name Ernst & Young LLP  
Auditor Location Boston, Massachusetts